Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PFE logo PFE
Upturn stock ratingUpturn stock rating
PFE logo

Pfizer Inc (PFE)

Upturn stock ratingUpturn stock rating
$25.62
Last Close (24-hour delay)
Profit since last BUY5.43%
upturn advisory
Consider higher Upturn Star rating
BUY since 19 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

07/08/2025: PFE (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

25 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $29.24

1 Year Target Price $29.24

Analysts Price Target For last 52 week
$29.24 Target price
52w Low $20.53
Current$25.62
52w High $29.98

Analysis of Past Performance

Type Stock
Historic Profit -6.8%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 07/08/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 144.29B USD
Price to earnings Ratio 18.29
1Y Target Price 29.24
Price to earnings Ratio 18.29
1Y Target Price 29.24
Volume (30-day avg) 25
Beta 0.49
52 Weeks Range 20.53 - 29.98
Updated Date 07/8/2025
52 Weeks Range 20.53 - 29.98
Updated Date 07/8/2025
Dividends yield (FY) 7.10%
Basic EPS (TTM) 1.38

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 12.62%
Operating Margin (TTM) 35.17%

Management Effectiveness

Return on Assets (TTM) 4.79%
Return on Equity (TTM) 8.62%

Valuation

Trailing PE 18.29
Forward PE 8.64
Enterprise Value 187473627415
Price to Sales(TTM) 2.31
Enterprise Value 187473627415
Price to Sales(TTM) 2.31
Enterprise Value to Revenue 3
Enterprise Value to EBITDA 10.88
Shares Outstanding 5685369856
Shares Floating 5675927880
Shares Outstanding 5685369856
Shares Floating 5675927880
Percent Insiders 0.06
Percent Institutions 67.55

ai summary icon Upturn AI SWOT

Pfizer Inc

stock logo

Company Overview

overview logo History and Background

Pfizer Inc. was founded in 1849 by Charles Pfizer and Charles Erhart in New York City. Initially, it produced fine chemicals, but it quickly expanded into pharmaceuticals. Key milestones include the development of penicillin during World War II and the introduction of blockbuster drugs like Viagra and Lipitor.

business area logo Core Business Areas

  • Biopharmaceuticals: Focuses on innovative medicines and vaccines, including therapies for oncology, inflammation & immunology, rare diseases, and vaccines.

leadership logo Leadership and Structure

Albert Bourla serves as the Chairman and CEO. The organizational structure is divided into various business units based on therapeutic areas and functions such as research, development, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • Comirnaty (COVID-19 Vaccine): An mRNA vaccine developed in partnership with BioNTech. Revenue in 2023 was $11.2 billion. Competitors include Moderna and Novavax.
  • Paxlovid (COVID-19 Treatment): An oral antiviral for the treatment of COVID-19. Revenue in 2023 was $1.3 billion. Competitors include Gilead Sciences.
  • Prevnar Family: A pneumococcal vaccine. It prevents pneumococcal disease. Competitors include Merck (Pneumovax 23).

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and increasing competition from generic drugs. Trends include personalized medicine, gene therapy, and biosimilars.

Positioning

Pfizer is a leading global pharmaceutical company with a strong portfolio of innovative medicines and vaccines. Its competitive advantages include its extensive R&D capabilities, global reach, and strong brand recognition.

Total Addressable Market (TAM)

The global pharmaceutical market is estimated to be over $1 trillion. Pfizer is well-positioned to capture a significant share of this market due to its diverse portfolio and global presence.

Upturn SWOT Analysis

Strengths

  • Strong R&D capabilities
  • Global presence and distribution network
  • Diverse portfolio of products
  • Strong brand recognition
  • Significant financial resources

Weaknesses

  • Dependence on key products (patent cliffs)
  • Exposure to generic competition
  • High R&D costs
  • Litigation risks
  • Integration risks from acquisitions

Opportunities

  • Expanding into emerging markets
  • Developing new therapies for unmet medical needs
  • Acquiring promising biotech companies
  • Leveraging digital technologies
  • Partnerships to expand product portfolios

Threats

  • Increasing competition from generic and biosimilar drugs
  • Stringent regulatory requirements
  • Price pressures from governments and payers
  • Product liability lawsuits
  • Economic downturns affecting healthcare spending

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • MRK
  • ABBV
  • NVS
  • BMY

Competitive Landscape

Pfizer faces intense competition from other large pharmaceutical companies. Its competitive advantages include its strong R&D capabilities and global reach, but it also faces challenges from generic competition and price pressures.

Major Acquisitions

Arena Pharmaceuticals

  • Year: 2022
  • Acquisition Price (USD millions): 6700
  • Strategic Rationale: Expanded Pfizer's capabilities in gastroenterology and inflammation & immunology.

Growth Trajectory and Initiatives

Historical Growth: Pfizer's growth has been driven by successful product launches, acquisitions, and expansion into new markets. However, patent expirations and competition have impacted growth at times.

Future Projections: Analysts project moderate revenue growth in the coming years, driven by new product launches and expansion in emerging markets. Earnings growth is expected to be higher due to cost-cutting measures and operational efficiencies.

Recent Initiatives: Pfizer is focusing on developing innovative therapies for oncology, inflammation & immunology, and rare diseases. It is also investing in digital technologies and personalized medicine.

Summary

Pfizer is a global pharmaceutical giant with a strong portfolio and extensive reach. While facing challenges from patent expirations and competition, its robust R&D and strategic acquisitions support future growth. Monitoring new product pipeline and maintaining financial stability will be critical. Demand swings in COVID products, and other risks can significantly affect their outlook and must be watched for by investors

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Pfizer's Investor Relations Website
  • SEC Filings
  • Analyst Reports
  • Company Press Releases

Disclaimers:

The data provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and based on available estimates. Actual results may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pfizer Inc

Exchange NYSE
Headquaters New York, NY, United States
IPO Launch date 2012-08-13
Chairman of the Board & CEO Dr. Albert Bourla D.V.M., Ph.D.
Sector Healthcare
Industry Drug Manufacturers - General
Full time employees 81000
Full time employees 81000

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Octagam, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.